Chapter 8: Antiarrhythmic Drugs — Module 2: Class I Agents — Sodium Channel Blockers Tier: Tier 2 — Conceptual Application & Drug Interactions (13 questions)
1. A 59-year-old man with paroxysmal atrial fibrillation and no structural heart disease has known sinus node dysfunction with resting heart rates of 42 to 52 beats per minute on his Holter. He does not have a pacemaker. His pulmonary function is normal. His cardiologist is choosing between flecainide and propafenone for AF rhythm control. Which of the following best explains why flecainide is preferable in this specific patient?
A) Flecainide is preferred because its stronger sodium channel blockade in atrial tissue provides more reliable AF rhythm control than propafenone in patients with slow sinus rates, where rate-dependent drug effects are most pronounced
B) Propafenone is preferred because its weak beta-blocking effect will reduce excessive sympathetic surges that trigger AF episodes in patients with sinus node dysfunction, providing simultaneous antiarrhythmic and chronotropic stabilization
C) Flecainide is preferred because propafenone's weak beta-adrenergic blocking properties can further suppress sinus node automaticity and worsen bradycardia in a patient already exhibiting resting heart rates of 42 to 52 beats per minute without pacemaker backup; flecainide lacks beta-blocking activity and therefore does not carry this additional risk of symptomatic bradycardia or sinus arrest in sinus node disease
D) Flecainide is preferred because propafenone is contraindicated in all patients with sinus rates below 60 beats per minute regardless of structural status, as its calcium channel blocking properties directly suppress pacemaker cell automaticity through L-type calcium channel inhibition in sinoatrial nodal cells
E) The two agents are equivalent in this patient; sinus node dysfunction is not a relevant differentiating factor between flecainide and propafenone because both drugs affect the sinus node equally through their shared Class Ic sodium channel blocking mechanism
ANSWER: C
Rationale:
Within the Class Ic subgroup, flecainide and propafenone have identical primary mechanisms but differ importantly in their secondary pharmacological properties. Propafenone possesses weak beta-adrenergic blocking activity (approximately one-fortieth the potency of propranolol) and weak L-type calcium channel blocking activity. In a patient with pre-existing sinus node dysfunction manifesting as resting bradycardia of 42 to 52 beats per minute, even modest additional beta-blockade from propafenone can further suppress sinus node automaticity, worsen bradycardia, or precipitate symptomatic pauses or sinus arrest ; particularly without the safety net of a pacemaker. Flecainide lacks beta-blocking activity and does not carry this specific risk in sinus node disease. This is one of two clinical contexts where the distinction between flecainide and propafenone is clinically important (the other being reactive airway disease).
Option A: Option A is incorrect: the two agents have comparable Class Ic efficacy for AF rhythm control; the selection here is driven by their differing secondary pharmacological profiles, not by differential sodium channel blocking potency.
Option B: Option B is incorrect: propafenone is contraindicated or at minimum problematic in this patient; its beta-blocking effect would worsen, not stabilize, sinus node function in a patient with pre-existing bradycardia and no pacemaker.
Option D: Option D is incorrect: propafenone's relative contraindication in sinus node dysfunction is through its beta-blocking properties, not through calcium channel-mediated direct pacemaker cell suppression; there is no absolute sinus rate cutoff of 60 beats per minute in the prescribing label, and the mechanism described is inaccurate.
Option E: Option E is incorrect: sinus node dysfunction is a clinically important differentiating factor; propafenone's beta-blocking activity creates an additional risk in this specific context that flecainide does not.
2. A 63-year-old man with atrial flutter is on propafenone 300 mg three times daily for rhythm control. His cardiologist adds quinidine 200 mg three times daily for additional antiarrhythmic effect. Two weeks later the patient reports progressive fatigue, exertional dyspnea, and lightheadedness. His resting heart rate has fallen from 68 to 44 beats per minute and his blood pressure is 102/64 mmHg. Which of the following best explains this clinical deterioration?
A) Quinidine is a potent inhibitor of cytochrome P450 2D6 (CYP2D6), the primary hepatic enzyme responsible for propafenone metabolism; CYP2D6 inhibition by quinidine substantially reduces propafenone clearance, raising plasma propafenone concentrations and dramatically amplifying its weak beta-adrenergic blocking effect, producing symptomatic bradycardia and hypotension
B) Quinidine's antimuscarinic properties have produced additive anticholinergic toxicity when combined with propafenone's own antimuscarinic effects, causing paradoxical sinus bradycardia through cholinergic rebound after initial tachycardia from direct M2 blockade
C) The combination of two Class I antiarrhythmic agents produces pharmacodynamic synergy at sodium channels, causing excessive QRS widening and His-Purkinje conduction block that manifests as bradycardia from complete AV block; the correct management is temporary pacing
D) Quinidine displaces propafenone from plasma protein binding sites, raising the free fraction of propafenone and producing transient enhanced pharmacodynamic effect; the bradycardia will resolve within 48 hours as protein binding re-equilibrates without any dose adjustment
E) The combination produces additive IKr blockade because both quinidine (Class Ia) and propafenone (Class Ic) block IKr potassium channels; the resulting QT prolongation has reduced the effective ventricular rate through reverse use-dependence, slowing the heart rate to 44 beats per minute
ANSWER: A
Rationale:
This is a clinically important pharmacokinetic drug-drug interaction. Propafenone undergoes extensive hepatic metabolism by CYP2D6, which converts it to its primary metabolite 5-hydroxypropafenone. Quinidine is a potent CYP2D6 inhibitor ; one of the most potent in clinical use. When quinidine inhibits CYP2D6, propafenone clearance is dramatically reduced, plasma propafenone concentrations rise substantially, and the drug's secondary pharmacological properties are amplified proportionally. In particular, propafenone's weak beta-adrenergic blocking activity (approximately one-fortieth the potency of propranolol at standard doses) becomes clinically significant as concentrations rise ; equivalent to administering a much higher effective beta-blocker dose. The result is symptomatic bradycardia (heart rate 44 beats per minute), hypotension, and fatigue. Management requires reducing or stopping propafenone; an alternative combination must be considered. This interaction illustrates why combining CYP2D6 inhibitors with propafenone requires caution.
Option B: Option B is incorrect: propafenone does not have antimuscarinic properties; the mechanism described is pharmacologically fabricated.
Option C: Option C is incorrect: while combining two Class I agents does increase sodium channel blockade, sinus bradycardia from His-Purkinje conduction block is not the primary mechanism; the interaction here is pharmacokinetic through CYP2D6 inhibition amplifying propafenone's beta-blocking effect.
Option D: Option D is incorrect: protein binding displacement is not the mechanism of this interaction and does not produce the sustained, clinically significant bradycardia seen here; the effect is pharmacokinetic through enzyme inhibition, not protein binding competition.
Option E: Option E is incorrect: propafenone does not have clinically significant IKr-blocking properties and does not prolong the QT interval; QT-mediated rate slowing through reverse use-dependence is not the mechanism; the bradycardia here is from enhanced beta-blockade.
3. A patient with severe heart failure (LVEF 18%, cardiac output 2.8 L/min) requires intravenous lidocaine for VT suppression. Compared with a patient with normal cardiac function receiving standard lidocaine dosing (bolus 1.5 mg/kg, infusion 3 mg/min), which of the following correctly describes how lidocaine pharmacokinetics are altered in this patient and how dosing should be adjusted?
A) Both the bolus and the infusion rate should be increased in heart failure; the reduced cardiac output impairs distribution of lidocaine to peripheral tissue, creating a smaller apparent volume of distribution that necessitates higher plasma concentrations to achieve the same tissue concentrations
B) The bolus dose should be increased because impaired hepatic function in heart failure reduces first-pass metabolism of the loading dose; the infusion rate should be kept the same because chronic heart failure upregulates CYP3A4 (cytochrome P450 3A4) in hepatic tissue, compensating for reduced hepatic blood flow
C) No dose adjustment is required; lidocaine pharmacokinetics are determined by its intrinsic hepatic extraction ratio, which is independent of hepatic blood flow and cardiac output in patients with normal liver architecture
D) The bolus dose should be kept the same but the infusion rate should be increased; reduced cardiac output impairs peripheral tissue uptake of lidocaine, requiring a higher infusion rate to maintain central compartment concentrations within the therapeutic range
E) Both the bolus dose and the maintenance infusion rate should be reduced in severe heart failure; reduced cardiac output decreases central compartment volume, so a standard bolus produces higher peak plasma concentrations requiring dose reduction; simultaneously, reduced hepatic blood flow impairs lidocaine clearance, causing drug accumulation at standard infusion rates ; a lower infusion rate (typically 1 to 2 mg/min) is required to prevent toxicity
ANSWER: E
Rationale:
Severe heart failure produces two simultaneous pharmacokinetic changes that both require downward dose adjustment of lidocaine. First, reduced cardiac output reduces tissue perfusion and limits the central-to-peripheral distribution of lidocaine, effectively reducing the initial volume of distribution (the central compartment). A standard bolus of 1.5 mg/kg produces higher peak plasma concentrations in this smaller central compartment than in a patient with normal cardiac output, increasing the risk of early CNS toxicity. The bolus dose should be reduced ; typically to 0.5 to 1.0 mg/kg ; and given more slowly to allow distribution. Second, lidocaine has a high hepatic extraction ratio and its clearance is primarily limited by hepatic blood flow rather than intrinsic enzymatic capacity. Severe heart failure dramatically reduces hepatic blood flow, reducing lidocaine clearance and causing accumulation at standard infusion rates. The maintenance infusion rate must be reduced accordingly.
Option A: Option A is incorrect: both bolus and infusion should be reduced, not increased; the smaller central compartment means peak concentrations are higher with standard dosing, not lower.
Option B: Option B is incorrect: lidocaine is an intravenous drug with no first-pass effect relevant to the bolus; heart failure does not upregulate CYP3A4; the primary clearance determinant is hepatic blood flow, which is reduced.
Option C: Option C is incorrect: lidocaine has a high hepatic extraction ratio and its clearance is highly blood-flow-dependent; reduced cardiac output significantly impairs lidocaine clearance and this cannot be ignored in dosing.
Option D: Option D is incorrect: reducing peripheral uptake does not require a higher infusion rate; the central compartment peak from the bolus is already higher, and the reduced clearance requires a lower infusion rate to prevent accumulation.
4. A 58-year-old woman is admitted from a nursing facility on an unknown antiarrhythmic agent. Her ECG shows a QRS duration of 126 ms (baseline 88 ms) and a QTc of 498 ms (baseline 420 ms). She is hemodynamically stable. Which of the following correctly identifies the most likely Class I subclass responsible for this ECG pattern and explains the mechanism?
A) Class Ic agent; marked QRS widening from slow-recovery sodium channel block is the hallmark of Class Ic agents; the QTc prolongation represents a secondary effect of excessive sodium channel accumulation causing voltage-dependent impairment of IKr potassium channel function at toxic concentrations
B) Class Ia agent; the combination of moderate QRS widening from sodium channel blockade and QTc prolongation from concurrent IKr potassium channel blockade is the characteristic dual ECG signature of Class Ia agents (quinidine, procainamide, disopyramide); Class Ic agents produce QRS widening without significant QTc change, and Class Ib agents produce neither
C) Class Ib agent; lidocaine and mexiletine produce QRS widening at therapeutic concentrations through their fast-recovery sodium channel block, and the concurrent QTc shortening from action potential duration reduction is being misread as QTc prolongation due to T-wave morphology alteration
D) The ECG pattern is non-specific and cannot distinguish between Class I subclasses; all Class I agents produce combined QRS widening and QTc prolongation at therapeutic concentrations, with the degree of each change proportional to the plasma drug concentration
E) Class Ic agent at supratherapeutic concentrations; at toxic levels, Class Ic agents block IKr in addition to sodium channels, producing this combined QRS and QTc pattern; at therapeutic concentrations, Class Ic agents produce only QRS widening
ANSWER: B
Rationale:
The ECG pattern of combined moderate QRS widening (38 percent increase) and significant QTc prolongation (78 ms increase) is the characteristic dual signature of Class Ia antiarrhythmic agents. Class Ia agents (quinidine, procainamide, disopyramide) produce this pattern through two simultaneous pharmacological effects: sodium channel blockade slows intraventricular conduction and widens the QRS, while concurrent IKr potassium channel blockade prolongs action potential duration and the QTc interval. This dual ECG effect distinguishes Class Ia agents from the other two subclasses. Class Ic agents (flecainide, propafenone) produce marked QRS widening without significant QTc change because they have negligible IKr blocking activity ; the absence of QTc prolongation is a defining feature of Class Ic. Class Ib agents (lidocaine, mexiletine) produce minimal QRS change and actually shorten action potential duration, producing no QTc prolongation. In this patient, the combination of both ECG changes strongly suggests a Class Ia agent, which should prompt investigation for quinidine, procainamide, or disopyramide in the medication reconciliation.
Option A: Option A is incorrect: Class Ic agents do not produce clinically significant QTc prolongation at any dose through voltage-dependent IKr impairment; the absence of IKr blockade is an intrinsic pharmacological property of Class Ic agents, not a dose-dependent phenomenon.
Option C: Option C is incorrect: Class Ib agents produce minimal QRS widening and no QTc prolongation; they shorten action potential duration and QTc rather than prolonging it; T-wave morphology changes do not explain a QTc of 498 ms.
Option D: Option D is incorrect: Class I subclasses have distinct and clinically distinguishable ECG profiles; the dual QRS widening plus QTc prolongation pattern specifically identifies Class Ia agents.
Option E: Option E is incorrect: Class Ic agents do not block IKr at any clinically relevant concentration; their lack of QTc prolongation is not dose-dependent but pharmacologically inherent.
5. A 34-year-old man with known Wolff-Parkinson-White syndrome presents with an irregular wide-complex tachycardia at a ventricular rate of 190 beats per minute. His blood pressure is 108/72 mmHg and he is alert. His ECG confirms pre-excited atrial fibrillation with varying RR intervals and delta waves. Which of the following represents the most appropriate pharmacological management for this hemodynamically stable presentation?
A) Intravenous amiodarone 150 mg over 10 minutes; amiodarone's multi-class mechanism including Class III potassium channel block slows both AV nodal and accessory pathway conduction, making it the preferred agent for pre-excited AF in hemodynamically stable patients
B) Intravenous metoprolol 5 mg over 2 minutes; beta-adrenergic blocking agents reduce sympathetic drive that accelerates accessory pathway conduction in pre-excited AF, and the rate-limiting effect at the AV node provides additional protection against rapid ventricular rates
C) Intravenous verapamil 5 to 10 mg over 2 minutes; calcium channel blockers slow AV nodal conduction and reduce the ventricular rate without affecting accessory pathway refractoriness, providing safe rate control while the patient is observed for spontaneous cardioversion
D) Intravenous procainamide 15 mg/kg administered over 30 to 60 minutes; procainamide is the pharmacological agent of choice for hemodynamically stable pre-excited AF because it slows conduction and prolongs refractoriness in the accessory pathway itself, reducing the ventricular rate and potentially terminating the arrhythmia without the risk of accelerating conduction through the accessory pathway
E) Intravenous adenosine 6 mg rapid bolus; adenosine's ultra-short half-life limits any adverse effects to seconds, and its ability to block AV nodal conduction will safely reduce the ventricular rate by forcing all conduction through the accessory pathway, which has a lower intrinsic rate than the AV node
ANSWER: D
Rationale:
Pre-excited atrial fibrillation in WPW syndrome requires an antiarrhythmic agent that acts on the accessory pathway rather than the AV node. The accessory pathway lacks the decremental conduction properties of the AV node and can conduct AF impulses at extremely rapid rates, producing the risk of ventricular fibrillation. Procainamide is the pharmacological agent of choice for hemodynamically stable pre-excited AF: as a Class Ia sodium channel blocker, it slows conduction velocity and prolongs refractoriness in accessory pathway tissue, reducing the rate of ventricular activation through the pathway and potentially terminating the arrhythmia. Ibutilide is an alternative. For hemodynamically unstable patients, immediate DC cardioversion takes priority. Options A, B, C, and E all describe AV nodal blocking agents or drugs that predominantly affect AV nodal conduction ; all of these are contraindicated in pre-excited AF.
Option A: Option A is incorrect: amiodarone is generally avoided in pre-excited AF because it primarily slows AV nodal conduction; in some cases it may paradoxically accelerate conduction through the accessory pathway by shifting the balance of conduction away from the AV node; it is not the preferred agent for stable pre-excited AF.
Option B: Option B is incorrect: beta-blockers are AV nodal blocking agents and are absolutely contraindicated in pre-excited AF; blocking the AV node redirects all AF conduction through the accessory pathway, potentially accelerating the ventricular rate to dangerous levels.
Option C: Option C is incorrect: verapamil is absolutely contraindicated in pre-excited AF for the same reason as beta-blockers ; it blocks AV nodal conduction and can cause life-threatening acceleration of ventricular rate through the accessory pathway.
Option E: Option E is incorrect: adenosine is contraindicated in pre-excited AF; it is a potent AV nodal blocker and can precipitate ventricular fibrillation by redirecting all AF conduction through the unprotected accessory pathway.
6. A pharmacist reviewing antiarrhythmic dosing schedules notes that disopyramide immediate-release is prescribed twice daily while amiodarone is prescribed once daily, yet both are used for rhythm control. A resident asks why dosing frequency differs so dramatically between these agents. Which of the following best explains this difference in terms of the pharmacokinetic basis for each drug's dosing interval?
A) Disopyramide requires twice-daily dosing because it undergoes saturable hepatic metabolism at therapeutic doses; as concentrations rise, enzyme saturation slows elimination and extends the effective half-life, requiring less frequent dosing than would be predicted from single-dose pharmacokinetics
B) Amiodarone's once-daily dosing reflects its mechanism of action rather than its half-life; amiodarone produces irreversible blockade of potassium channels, so a single daily dose permanently alters channel function for 24 hours regardless of plasma drug concentration
C) Disopyramide has a half-life of approximately 6 to 8 hours, requiring dosing every 6 to 8 hours (three to four times daily) for the immediate-release formulation to maintain therapeutic plasma concentrations; amiodarone has an extraordinarily long terminal half-life of 40 to 55 days from extensive tissue sequestration, meaning a single daily dose maintains stable plasma concentrations; this pharmacokinetic difference ; not mechanism ; drives the dosing frequency contrast
D) Disopyramide's twice-daily dosing reflects its dual mechanism requiring both sodium channel and IKr blockade to be continuously occupied; amiodarone requires only once-daily dosing because its Class III mechanism operates exclusively during sleep when vagal tone predominates
E) The dosing difference reflects renal versus hepatic elimination; disopyramide is renally eliminated with a short renal half-life requiring frequent dosing, while amiodarone's hepatic elimination produces a long half-life allowing once-daily dosing; the difference in elimination route is the pharmacokinetic basis
ANSWER: C
Rationale:
The dramatic difference in dosing frequency between disopyramide and amiodarone is entirely explained by their half-lives. Disopyramide has a half-life of approximately 6 to 8 hours, meaning plasma concentrations fall to approximately half their peak value within that time. To maintain therapeutic concentrations continuously ; necessary for antiarrhythmic effect ; the immediate-release formulation must be given three to four times daily. A controlled-release (CR) formulation of disopyramide allows twice-daily dosing by extending the absorption phase. Amiodarone, by contrast, has an extraordinarily long terminal half-life of approximately 40 to 55 days, attributable to its massive volume of distribution and extensive sequestration in adipose tissue, liver, lung, and other organs. After loading, plasma concentrations decline so slowly that a single daily maintenance dose is sufficient to maintain stable tissue and plasma concentrations.
Option A: Option A is incorrect: disopyramide does not undergo saturable hepatic metabolism that extends its effective half-life; the prescription of twice-daily dosing for the example in this question is actually insufficient ; immediate-release disopyramide requires TID or QID dosing; the pharmacokinetics are straightforward first-order kinetics.
Option B: Option B is incorrect: amiodarone does not produce irreversible channel blockade; its effects are reversible and concentration-dependent; once-daily dosing reflects its long half-life, not channel irreversibility.
Option D: Option D is incorrect: the mechanism described ; dual-occupancy requirement for sodium and IKr channels ; is pharmacologically fabricated; amiodarone does not have a sleep-phase mechanism.
Option E: Option E is incorrect: while disopyramide does have significant renal elimination, the dosing frequency difference is primarily explained by half-life, not by the route of elimination per se; the half-life of amiodarone is long because of tissue distribution, not simply because it is hepatically cleared.
7. A 67-year-old man with ischemic cardiomyopathy (LVEF 28%) has an implantable cardioverter-defibrillator (ICD) that has delivered multiple appropriate shocks for sustained VT despite maximum-dose amiodarone. His electrophysiologist proposes adding mexiletine to his amiodarone regimen rather than substituting another drug. Which of the following best explains the pharmacological rationale for this combination?
A) Mexiletine and amiodarone have complementary mechanisms that produce additive antiarrhythmic suppression without pharmacodynamic duplication: mexiletine provides rapid-kinetics sodium channel blockade with preferential activity in ischemic and depolarized tissue (Class Ib), while amiodarone provides multi-class sodium channel block at slower kinetics, IKr blockade, beta-blockade, and calcium channel blockade; combining agents with mechanistically distinct profiles is a rational strategy for refractory VT in structural heart disease where amiodarone alone is insufficient
B) Mexiletine should not be added to amiodarone in structural heart disease; mexiletine is a Class Ib agent and all Class I agents are contraindicated in patients with structural heart disease based on the CAST trial principle, which applies equally to all three Class I subclasses
C) The combination is pharmacokinetically beneficial because amiodarone inhibits CYP3A4 and reduces mexiletine metabolism, raising mexiletine plasma concentrations to supratherapeutic levels that suppress VT circuits that respond inadequately to standard doses of either drug alone
D) Mexiletine is added because amiodarone at maximum dose has saturated IKr channels; mexiletine compensates by blocking the residual unsaturated IKr channels in ischemic tissue through a complementary potassium channel blocking mechanism that amiodarone alone cannot achieve
E) The combination is irrational because both mexiletine and amiodarone block sodium channels, producing purely additive toxicity without mechanistic complementarity; substituting a Class III agent such as sotalol would be more appropriate for refractory VT in structural heart disease
ANSWER: A
Rationale:
Mexiletine-amiodarone combination therapy is a well-established approach for refractory VT in patients with structural heart disease who have inadequate VT suppression on amiodarone alone. The rationale is mechanistic complementarity. Amiodarone is a multi-class agent with sodium channel blocking activity at slower kinetics (resembling Class Ib at therapeutic concentrations), IKr potassium channel blockade (Class III), non-selective beta-blockade (Class II), and calcium channel blockade (Class IV). Despite this broad mechanistic coverage, some VT circuits in ischemic myocardium remain refractory. Mexiletine adds rapid-kinetics Class Ib sodium channel blockade with preferential activity in ischemic and depolarized tissue ; a mechanistic contribution that is distinct from and complementary to amiodarone's sodium channel effects. Clinical data support this combination in reducing VT burden and ICD shock frequency.
Option B: Option B is incorrect: the CAST contraindication applies specifically to Class Ic agents in post-MI structural disease; Class Ib agents (mexiletine, lidocaine) are not contraindicated in structural heart disease and are routinely used for VT suppression in ischemic cardiomyopathy.
Option C: Option C is incorrect: while amiodarone does inhibit multiple CYP enzymes including CYP2D6 (relevant to propafenone) and CYP2C9 (relevant to warfarin), the rationale for the combination is not pharmacokinetic drug level elevation ; the antiarrhythmic benefit is through mechanistic complementarity at appropriate plasma concentrations.
Option D: Option D is incorrect: mexiletine does not block IKr potassium channels; it is a sodium channel blocker; IKr channel saturation is not a relevant concept for amiodarone dosing.
Option E: Option E is incorrect: sotalol is contraindicated in this patient with LVEF 28% due to its negative inotropic and proarrhythmic risks in severe HFrEF; the mechanistic characterization of the mexiletine-amiodarone combination as purely additive toxicity without complementarity is incorrect.
8. A pharmacology faculty member is teaching the mechanism by which Class Ic agents cause proarrhythmia in structural heart disease. Which of the following best explains the electrophysiological basis for Class Ic proarrhythmia specifically in ischemic myocardium?
A) Class Ic agents cause proarrhythmia by prolonging the QT interval through IKr blockade, which creates the substrate for early afterdepolarizations and torsades de pointes; the risk is amplified in ischemic myocardium because ischemia depletes intracellular potassium, further prolonging repolarization
B) Class Ic agents cause proarrhythmia by producing complete sodium channel blockade in ischemic tissue, creating zones of electrical silence that anchor re-entrant circuits; the mechanism is identical to Class Ib agents but occurs at lower drug concentrations in ischemic myocardium because of the higher density of inactivated channels
C) Class Ic agents cause proarrhythmia by blocking the Na+/K+-ATPase pump in ischemic cardiomyocytes, producing intracellular calcium overload through the sodium-calcium exchanger, which triggers delayed afterdepolarizations and spontaneous phase 4 depolarization-mediated VT
D) Class Ic agents cause proarrhythmia exclusively through a pharmacodynamic interaction with sympathetic nerve terminals in ischemic myocardium; catecholamine release from injured adrenergic neurons activates residual sodium channels not blocked by the drug, producing triggered automaticity that overcomes the antiarrhythmic effect
E) Class Ic agents cause proarrhythmia through their slow-recovery sodium channel kinetics combined with the heterogeneous conduction properties of ischemic myocardium: in peri-infarct tissue, channels recover at variable rates depending on local membrane potential and tissue composition; slow-recovery block accumulates differentially across this heterogeneous substrate, converting areas of functional conduction delay into fixed unidirectional block, creating new anatomical re-entrant circuits that sustain monomorphic VT ; the same drug effect that is benign in homogeneous normal myocardium becomes proarrhythmic in heterogeneous diseased tissue
ANSWER: E
Rationale:
The proarrhythmic mechanism of Class Ic agents in structural heart disease is substrate-dependent and requires the combination of two factors: the drug's pharmacological properties and the electrophysiological heterogeneity of ischemic myocardium. Peri-infarct myocardium contains a mixture of normal, injured, and fibrotic cells with heterogeneous sodium channel density, resting membrane potential, and action potential morphology. In this setting, the slow-recovery kinetics of Class Ic agents ; block that cannot fully dissipate during the diastolic interval at physiological rates ; produce variable degrees of channel block across different tissue regions. Areas with more depolarized resting potentials (ischemic tissue) have more channels in the inactivated state and accumulate more block. This spatial heterogeneity of conduction slowing converts functional conduction delay ; which might have been antiarrhythmic in normal tissue ; into fixed unidirectional block in some pathways and slow conduction in others, creating the re-entrant circuit geometry required for sustained monomorphic VT. In homogeneous structurally normal myocardium, the same drug effect is distributed uniformly and is antiarrhythmic rather than proarrhythmic. This is why the CAST contraindication is specifically substrate-dependent ; the drug is dangerous in diseased myocardium, not in normal myocardium.
Option A: Option A is incorrect: QT prolongation and torsades de pointes are the proarrhythmic mechanisms of Class Ia and Class III agents; Class Ic agents do not significantly block IKr and do not prolong the QT interval; their proarrhythmia is monomorphic VT from re-entry, not polymorphic TdP.
Option B: Option B is incorrect: complete sodium channel blockade producing electrical silence is not the mechanism; Class Ic agents produce conduction slowing, not complete block, and the critical element is heterogeneous rather than complete blockade; the mechanism is also not identical to Class Ib, which has fast recovery kinetics and a completely different proarrhythmic profile.
Option C: Option C is incorrect: Class Ic agents do not inhibit the Na+/K+-ATPase; this mechanism describes digitalis toxicity; Class Ic agents act through voltage-gated sodium channel blockade.
Option D: Option D is incorrect: catecholamine release from injured adrenergic terminals is not the established mechanism of Class Ic proarrhythmia; the mechanism is through altered conduction in heterogeneous ischemic tissue, not sympathetically triggered automaticity.
9. A 71-year-old woman with atrial flutter is started on quinidine without a co-prescribed AV nodal blocking agent. Three days later she is brought to the emergency department after a witnessed syncopal episode. The witness reports she was sitting quietly watching television when she suddenly lost consciousness for approximately 15 seconds and recovered spontaneously. Her 12-lead ECG shows sinus rhythm with a QTc of 514 ms. A prior ECG from six months ago showed a QTc of 418 ms. Her event monitor shows that the syncopal episode was preceded by a 2.4-second sinus pause followed by a 14-second run of irregular wide-complex tachycardia with a characteristic twisting morphology. Which of the following best explains both the mechanism of the arrhythmia and why it occurred at rest rather than during activity?
A) The arrhythmia represents quinidine-induced atrial flutter with 1:1 conduction; the pause preceded by sinus node suppression from quinidine's sodium channel block in sinoatrial tissue allowed the flutter circuit to accelerate without AV nodal protection; the irregular wide-complex appearance resulted from variable bundle branch aberration during the rapid ventricular response
B) The arrhythmia is quinidine-induced torsades de pointes; quinidine's IKr blockade has prolonged the QTc to 514 ms, creating the substrate for early afterdepolarization formation; the arrhythmia occurred at rest because quinidine's IKr block exhibits reverse use-dependence ; the blocking effect is most pronounced at slow heart rates and during pauses, producing maximum QTc prolongation and the greatest risk of TdP during bradycardia, rest, or post-ectopic pauses; this is the basis for the historical term "quinidine syncope"
C) The arrhythmia is catecholamine-induced polymorphic VT from quinidine's alpha-adrenergic blocking properties causing reflex sympathetic activation; the syncopal event at rest reflects peak catecholamine release during the transition from sympathetic to parasympathetic dominance in the evening, which unmasked a latent long QT substrate
D) The arrhythmia is quinidine-induced ventricular fibrillation from Class Ia sodium channel accumulation; at slow heart rates, quinidine's slow-recovery kinetics produce maximum sodium channel block in ventricular myocardium, reducing conduction velocity below the threshold for re-entrant circuit maintenance, which paradoxically destabilizes VF rather than organizing it to monomorphic VT
E) The arrhythmia represents acceleration-dependent bundle branch block triggered by the post-pause sinus beat; quinidine's sodium channel block in the right bundle branch has created a substrate where the faster post-pause sinus rate produces transient right bundle branch block and a wide-complex appearance misidentified as polymorphic VT
ANSWER: B
Rationale:
This is a textbook presentation of quinidine-induced torsades de pointes ; the arrhythmia historically known as "quinidine syncope." The QTc increase from 418 ms to 514 ms (96 ms prolongation) reflects quinidine's IKr blockade extending ventricular repolarization and creating the substrate for early afterdepolarizations. The characteristic twisting morphology of the wide-complex tachycardia and its 14-second duration are consistent with TdP. The critical mechanistic point is why TdP occurred at rest. Quinidine's IKr blockade exhibits reverse use-dependence: the blocking effect on IKr is most pronounced at slow heart rates, when the extended diastolic interval allows maximum drug-channel interaction time and most complete IKr blockade, producing the greatest action potential duration prolongation. The 2.4-second pause preceding the arrhythmia provides the classic pause-dependent trigger: the long RR interval further prolongs the action potential in the subsequent beat, bringing early afterdepolarizations to threshold and initiating TdP. This combination ; baseline IKr blockade prolonging the QTc at rest, amplified by a pause ; makes TdP most likely during bradycardia, pauses, or at rest rather than during exercise (where faster rates paradoxically provide some protection through reverse use-dependence working in the patient's favor).
Option A: Option A is incorrect: the event monitor shows a twisting wide-complex tachycardia (TdP morphology), not organized flutter waves with aberrancy; the 2.4-second pause before a tachyarrhythmia is the classic pause-TdP sequence, not a flutter acceleration pattern.
Option C: Option C is incorrect: alpha-adrenergic blocking properties of quinidine cause peripheral vasodilation, not sympathetically triggered polymorphic VT; catecholamine-induced polymorphic VT is the mechanism of CPVT (ryanodine receptor disease), not quinidine toxicity.
Option D: Option D is incorrect: quinidine's primary proarrhythmic mechanism at this presentation is TdP from IKr blockade, not VF from sodium channel accumulation; sodium channel block contributes to QRS widening but is not the mechanism of pause-triggered polymorphic arrhythmia here.
Option E: Option E is incorrect: bundle branch block from quinidine's sodium channel effect could produce a wide QRS but not a 14-second run of tachyarrhythmia with twisting morphology; acceleration-dependent BBB produces a fixed bundle branch pattern, not an irregular twisting tachycardia.
10. A 64-year-old man is admitted with an acute anterior myocardial infarction and requires a lidocaine infusion for VT suppression. His measured total lidocaine plasma level is 7.2 mcg/mL (above the standard therapeutic range of 1.5 to 5 mcg/mL), yet he has no symptoms of toxicity and his VT is well-controlled. His clinical team considers reducing the infusion rate. Which of the following best explains this apparent discrepancy and guides the correct management decision?
A) Lidocaine's therapeutic range of 1.5 to 5 mcg/mL was established in healthy volunteers and does not apply to critically ill patients; in acute MI, sodium channel upregulation increases the number of drug-binding targets, requiring higher total plasma concentrations to achieve equivalent sodium channel block; the measured level of 7.2 mcg/mL may represent appropriate target attainment in this clinical context
B) The measured level reflects an assay error; lidocaine assays in the acute post-MI setting frequently over-report total drug concentration because circulating catecholamines cross-react with the immunoassay antibody; the true plasma concentration is likely within the therapeutic range and the infusion rate should be maintained
C) Lidocaine at concentrations above 5 mcg/mL produces paradoxical sodium channel inactivation that is actually antiarrhythmic rather than toxic in ischemic tissue; the patient's absence of toxicity reflects the ischemic myocardium's protective buffering of high lidocaine concentrations through rapid intracellular drug sequestration
D) Lidocaine binds extensively to alpha-1 acid glycoprotein (AAG), an acute-phase reactant that rises significantly in the 24 to 72 hours following acute myocardial infarction and other acute illness; elevated AAG increases total lidocaine binding, raising the measured total concentration while the free (unbound, pharmacologically active) lidocaine fraction remains within the therapeutic range; it is the free concentration that drives both efficacy and toxicity, so the absence of toxicity at 7.2 mcg/mL total is expected and the infusion rate should not be reduced solely on the basis of the elevated total level
E) The patient has developed pharmacodynamic tolerance to lidocaine through sodium channel desensitization; repeated lidocaine binding has shifted sodium channel voltage-dependence, requiring higher total drug concentrations to achieve the same degree of channel blockade; the therapeutic range should be recalibrated upward to 5 to 10 mcg/mL for this patient
ANSWER: D
Rationale:
Lidocaine binds extensively to alpha-1 acid glycoprotein (AAG), an acute-phase reactant protein synthesized by the liver in response to acute illness, tissue injury, and inflammation. Following acute myocardial infarction, AAG concentrations rise substantially ; typically doubling within 24 to 72 hours of the acute event. This elevation in AAG increases the protein-bound fraction of total lidocaine, raising the measured total plasma concentration while the free (unbound) lidocaine concentration ; which is the pharmacologically active fraction driving both antiarrhythmic effect and toxicity ; remains relatively unchanged. Standard therapeutic ranges for lidocaine (1.5 to 5 mcg/mL) are based on total plasma concentration measurements in populations without elevated AAG. When AAG is elevated post-MI, the total concentration may exceed the standard range while the free concentration remains therapeutic and non-toxic. This explains why this patient has a total level of 7.2 mcg/mL without toxicity. The correct management is to assess clinical endpoints (VT suppression, absence of toxicity symptoms) rather than reduce the infusion solely to normalize the total level.
Option A: Option A is incorrect: sodium channel upregulation in acute MI is not an established pharmacological explanation for altered lidocaine therapeutic ranges; the correct explanation is AAG-mediated protein binding changes.
Option B: Option B is incorrect: catecholamine cross-reactivity with lidocaine immunoassays is not an established clinical phenomenon; the assay result is real, and the explanation lies in protein binding.
Option C: Option C is incorrect: lidocaine does not produce paradoxical antiarrhythmic inactivation at supratherapeutic total concentrations, and intracellular drug sequestration in ischemic myocardium is not an established buffering mechanism that prevents toxicity.
Option E: Option E is incorrect: pharmacodynamic sodium channel tolerance is not an established mechanism for lidocaine; the therapeutic range does not require individual upward recalibration; the explanation is pharmacokinetic through protein binding.
11. A 68-year-old woman with paroxysmal AF and no structural heart disease has a CrCl of 28 mL/min from diabetic nephropathy. Her cardiologist is choosing between flecainide and propafenone for rhythm control. Which of the following correctly describes how renal impairment affects the pharmacokinetics of each agent and guides the selection?
A) Both flecainide and propafenone require significant dose reduction in a CrCl of 28 mL/min because both agents are predominantly renally eliminated as unchanged drug; either can be used but doses of both must be reduced by approximately 50 percent with careful QRS and QTc monitoring
B) Propafenone requires dose reduction in renal impairment because its active metabolite 5-hydroxypropafenone accumulates in reduced renal function; flecainide does not require adjustment because it is completely metabolized by the liver before renal excretion and no unchanged drug appears in the urine
C) Flecainide undergoes significant renal elimination, with approximately 40 percent excreted as unchanged drug in the urine; in a patient with CrCl of 28 mL/min, flecainide clearance is substantially reduced, increasing the risk of drug accumulation and QRS toxicity, requiring dose reduction and careful monitoring; propafenone is predominantly hepatically eliminated with minimal renal clearance of unchanged drug and does not require dose adjustment for renal impairment, making it pharmacokinetically preferable in this patient
D) Neither agent requires dose adjustment for renal impairment; both flecainide and propafenone undergo complete hepatic biotransformation before any renal elimination, and their active metabolites are further conjugated in the liver to inactive glucuronide compounds that are cleared renally without accumulating to pharmacologically significant concentrations
E) Flecainide is preferable in renal impairment because its renal elimination provides a compensatory alternative clearance pathway; as CrCl declines, hepatic clearance upregulates proportionally through CYP2D6 induction, maintaining stable total flecainide clearance; propafenone, being entirely hepatic, loses this compensatory mechanism
ANSWER: C
Rationale:
Flecainide and propafenone differ importantly in their elimination pathways, and this distinction becomes clinically significant in renal impairment. Approximately 40 percent of flecainide is excreted unchanged in the urine, meaning renal clearance is a major elimination route. In a patient with CrCl of 28 mL/min, flecainide clearance is substantially reduced and drug accumulates if standard doses are used. Accumulation produces progressive QRS widening ; the pharmacodynamic marker of sodium channel toxicity ; and increases proarrhythmic risk. Dose reduction (typically to 50 percent of the standard dose) and careful QRS monitoring are required when flecainide is used in significant renal impairment. Propafenone, by contrast, is predominantly eliminated by hepatic metabolism (CYP2D6 to 5-hydroxypropafenone and CYP3A4 to N-depropylpropafenone), with minimal renal elimination of unchanged drug. Renal impairment does not significantly alter propafenone pharmacokinetics, and dose adjustment is not routinely required. In this patient with CrCl 28 mL/min, propafenone is the pharmacokinetically preferable Class Ic choice ; provided the patient has no structural heart disease, no asthma, and no sinus node dysfunction.
Option A: Option A is incorrect: propafenone does not require renal dose adjustment; its elimination is predominantly hepatic; the characterization of both agents requiring 50 percent dose reduction in renal failure is incorrect.
Option B: Option B is incorrect: 5-hydroxypropafenone does not significantly accumulate in renal impairment in a clinically meaningful way; and flecainide ; not propafenone ; is the agent requiring renal dose adjustment.
Option D: Option D is incorrect: flecainide is not completely hepatically biotransformed; approximately 40 percent is eliminated renally as unchanged drug ; this is the basis for its renal dose adjustment requirement.
Option E: Option E is incorrect: hepatic CYP2D6 does not upregulate proportionally to compensate for declining renal clearance of flecainide; this compensatory mechanism does not exist; declining CrCl produces genuine flecainide accumulation.
12. A 56-year-old man with paroxysmal AF, no structural heart disease, and coronary artery disease (without prior MI or reduced EF) requires rhythm control with a Class Ic agent. He is on metoprolol succinate 100 mg daily for angina, which is well-tolerated. His cardiologist is choosing between flecainide and propafenone. Which of the following pharmacokinetic consideration best guides agent selection in this patient?
A) Flecainide is preferred because propafenone is a potent inhibitor of cytochrome P450 2D6 (CYP2D6), the primary enzyme responsible for metoprolol metabolism; CYP2D6 inhibition by propafenone would substantially raise metoprolol plasma concentrations, producing excessive beta-blockade manifesting as symptomatic bradycardia, fatigue, and exercise intolerance; flecainide does not inhibit CYP2D6 and does not affect metoprolol metabolism
B) Propafenone is preferred because its intrinsic weak beta-blocking properties will allow the metoprolol dose to be reduced by 50 percent, simplifying the regimen and reducing the additive cardiac depressant effects of two agents with overlapping AV nodal activity
C) Flecainide is preferred because it induces CYP3A4, which accelerates metoprolol metabolism and reduces its plasma concentration; the resulting lower metoprolol levels allow better exercise tolerance during AF rhythm control without the bradycardia that would occur if metoprolol levels were maintained at pre-treatment concentrations
D) The two agents are pharmacokinetically equivalent in this patient because metoprolol is a CYP2D6 substrate and both flecainide and propafenone inhibit CYP2D6 with equal potency; the choice between them should be based on clinical factors such as the presence of asthma rather than drug interaction considerations
E) Propafenone is preferred because its hepatic CYP2D6 metabolism makes it a substrate rather than an inhibitor of this enzyme; co-administration with metoprolol produces competitive substrate inhibition that reduces both drugs' metabolism equally, achieving stable plasma concentrations of both agents without clinically significant interaction
ANSWER: A
Rationale:
Propafenone is metabolized by CYP2D6, and critically, it also inhibits CYP2D6 ; a property that creates clinically important drug interactions with co-administered CYP2D6 substrates. Metoprolol is a major CYP2D6 substrate: its plasma concentrations are highly sensitive to CYP2D6 inhibition, rising substantially when CYP2D6 is blocked. When propafenone inhibits CYP2D6, metoprolol clearance is reduced, plasma metoprolol concentrations rise, and the degree of beta-blockade increases ; producing symptomatic bradycardia, fatigue, exercise intolerance, and potential AV conduction disturbances. In a patient who is dependent on metoprolol for angina management and tolerating it well at his current dose, adding propafenone risks destabilizing this carefully titrated regimen. Flecainide does not inhibit CYP2D6 and does not affect metoprolol metabolism, making it the pharmacokinetically preferable choice in this patient.
Option B: Option B is incorrect: propafenone's weak beta-blocking properties do not rationalize a planned 50 percent metoprolol reduction; the concern is that propafenone's CYP2D6 inhibition raises metoprolol levels unpredictably; this approach would compound rather than simplify the drug interaction.
Option C: Option C is incorrect: flecainide does not induce CYP3A4 and does not accelerate metoprolol metabolism; the rationale for flecainide is its lack of CYP2D6 inhibition, not CYP3A4 induction.
Option D: Option D is incorrect: flecainide does not inhibit CYP2D6; this is a key pharmacokinetic difference between the two Class Ic agents; the statement that they have equal CYP2D6 inhibitory potency is incorrect.
Option E: Option E is incorrect: competitive substrate inhibition of this nature does not produce stable equivalent reduction in both drugs; propafenone is both a substrate and an inhibitor of CYP2D6, and its inhibitory effect on metoprolol metabolism is clinically significant and not self-balancing.
13. A 52-year-old man with non-obstructive hypertrophic cardiomyopathy (HCM; LVEF 65%, no LVOT obstruction, LV wall thickness 18 mm) has frequent symptomatic premature ventricular beats confirmed on Holter monitoring (1,800 PVBs per day). A consulting cardiologist suggests flecainide for PVB suppression, citing the patient's young age, preserved ejection fraction, and absence of prior MI. Which of the following best explains why this recommendation should be questioned?
A) Flecainide is appropriate in this patient because the CAST contraindication applies exclusively to post-myocardial infarction structural disease with ischemic scar; hypertrophic cardiomyopathy produces concentric hypertrophy without fibrosis, and the electrophysiological substrate differs fundamentally from post-MI scar, making the CAST principle inapplicable
B) Flecainide is appropriate because the patient's LVEF of 65% is well above the 40% threshold below which Class Ic agents are contraindicated; preserved ejection fraction is the key criterion for safe Class Ic use regardless of other structural abnormalities
C) Flecainide is appropriate because the patient's symptoms from PVBs represent a legitimate quality-of-life indication; the CAST contraindication applies to asymptomatic PVBs treated presumptively, but symptomatic PVBs with a clear quality-of-life impact justify Class Ic therapy in structural heart disease when the patient has been fully informed of the risk
D) Flecainide is contraindicated because LV wall thickness of 18 mm exceeds the threshold of 15 mm above which all antiarrhythmic agents are contraindicated in hypertrophic cardiomyopathy regardless of ejection fraction or arrhythmia type
E) The CAST principle extends beyond post-MI structural disease: the pharmacological mechanism underlying Class Ic proarrhythmia ; slow-recovery sodium channel block in heterogeneous, structurally abnormal myocardium creating new re-entrant circuits ; applies to any significant structural substrate, including hypertrophic cardiomyopathy with marked wall thickening; HCM myocardium is characterized by myocyte disarray, fibrosis, and heterogeneous conduction that creates a proarrhythmic substrate analogous to peri-infarct tissue; Class Ic agents are contraindicated in HCM regardless of ejection fraction; furthermore, PVB suppression as a surrogate endpoint does not predict survival benefit, as CAST demonstrated; beta-blockers or verapamil are more appropriate for symptomatic PVBs in this patient
ANSWER: E
Rationale:
The CAST trial specifically enrolled post-MI patients, but the pharmacological principle it established extends to all forms of significant structural heart disease that create heterogeneous myocardial conduction. Hypertrophic cardiomyopathy is characterized by myocyte disarray ; a disorganized arrangement of myocardial fibers ; interstitial fibrosis, small vessel disease, and heterogeneous action potential morphology across hypertrophied and non-hypertrophied regions. This structural substrate creates the same electrophysiological conditions that make Class Ic agents proarrhythmic in post-MI tissue: heterogeneous conduction with regions of slow and fast propagation that, in the presence of slow-recovery sodium channel block, can generate new re-entrant circuits. The fact that the LVEF is preserved (65%) does not mitigate this risk ; the CAST contraindication is not gated by ejection fraction. Similarly, the symptom-based rationale for treatment does not override the structural contraindication. Beta-blockers are first-line for symptomatic PVBs in HCM, with verapamil as an alternative; catheter ablation may be considered for refractory cases.
Option A: Option A is incorrect: while ischemic scar and HCM fibrosis differ histologically, both produce heterogeneous myocardial conduction that creates the substrate for Class Ic proarrhythmia; the CAST principle is pharmacological and substrate-dependent, not diagnosis-specific.
Option B: Option B is incorrect: there is no LVEF threshold of 40% below which Class Ic agents are contraindicated and above which they are safe; preserved ejection fraction does not eliminate proarrhythmic risk in structural heart disease.
Option C: Option C is incorrect: symptom-driven PVB treatment does not override the structural contraindication; CAST enrolled patients with symptomatic PVBs as well as asymptomatic ones, and demonstrated mortality harm regardless of symptom status.
Option D: Option D is incorrect: there is no established wall thickness threshold of 15 mm above which all antiarrhythmic agents are contraindicated; the Class Ic contraindication in HCM is based on the proarrhythmic substrate, not a wall thickness cutoff.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.